GENE THERAPY SOLUTIONS

TRANSIENT AAV
PRODUCTION

Our industry leading technology platform provides flexible, high titre rAAV production. Reconfigured Rep-Cap and modified Ad5 helper plasmids and GMP banked clonal suspension HEK293 cell line improve AAV yield and quality.

"OXGENE's AAV system is superior to
off-the-shelf plasmid systems for AAV titres"

Andy Topping, Chief Scientific Officer at FUJIFILM Diosynth
Biotechnologies

Transient AAV Production

Our transient expression platform comprises optimised proprietary XAAV™ plasmids and a GMP-banked clonal suspension HEK293 cell line. We have reconfigured the Rep and Cap genes to place Cap under the control of a strong CMV promoter, while Rep is expressed at a lower level via an EMCV internal ribosome entry site. This results in a higher viral titre, better per cell rAAV productivity and improved full:empty vector ratio. We've also improved adenoviral helper functionality by simplifying the Ad5 helper plasmid, which doesn't contain any adenoviral hexon genes; an added benefit when it comes to regulatory approval.

We offer expert cloning and engineering services to customise and optimise our XAAV™ plasmids for expression of your gene of interest, before process development and manufacture of your rAAV vectors at any grade and scale.

Reconfigured Rep-Cap improves viral titre by two to eight fold

rAAV production in suspension HEK293 cell line in shake flasks. Using OXGENE’s reconfigured Rep-Cap plasmid (red) improves viral titre between two and eight fold, depending on AAV serotype.

GMP-banked suspension clonal HEK293 cell line improves titre

Our clonal suspension HEK293 cell line (SP7D5, far left) displays improved characteristics for AAV production compared to the parental pool (far right). Graph shows rAAV5 production from HEK293OX_BCD clones and pool using optimised RepCap5 plasmid: viral genome titre (VG/mL; blue) and cell specific productivity (VG/transfected cell; red).

From our experts to yours; we offer comprehensive
technical support so you can have complete
confidence in our technologies.

TESSA™: Scalable AAV Production

High-titre, high quality, plasmid-free AAV production.

GENE THERAPY SOLUTIONS

TRANSIENT AAV PRODUCTION

"OXGENE's AAV system is superior to off-the-shelf plasmid systems for AAV titres"

Andy Topping, Chief Scientific Officer at FUJIFILM Diosynth Biotechnologies